Trilaciclib: Experimental Treatment for Small-Cell Lung Cancer (SCLC)
Scientific rationale and therapeutic potential
Trilaciclib is a short-acting CDK4/6 inhibitor given as an intravenous infusion prior to chemotherapy. Trilaciclib is designed to:
- preserve hematopoietic stem cell (HSPC) and immune system function during chemotherapy (myelopreservation);
- enable planned chemotherapy regimens and prime anti-tumor immunity;
- improve patient outcomes by reducing infections, hospitalizations, transfusions and growth-factor usage.
Clinical results (see: Publications)
Trilaciclib has potential in small-cell lung cancer (SCLC) based on:
- positive Phase 2a topline data in patients with first-line, extensive-stage SCLC in combination with carboplatin / etoposide (G1T28-02 trial, see below) showing robust myelopreservation benefits (view press release here);
- preliminary clinical data in patients with second / third-line SCLC in combination with topotecan (G1T28-03 trial, see below) presented at the 2016 World Conference on Lung Cancer;
- Phase 1 data in healthy volunteers presented at the American Society of Clinical Oncology 2015 Annual Meeting and published in Science Translational Medicine.
G1's ongoing Phase 2 trials in SCLC
|G1T28-02 Trial||G1T28-03 Trial||G1T28-05 Trial|